Nov 12, 2003
If given the following three options for intial therapy which would you choose or recommend, if any? Please help with this decision. Thanks for helping in advance.
2. LPV/RTV+2 NRTIS
3. EFV+2 NRTIS
| Response from Dr. Wohl
The three options you list happen to be the three arms of a US AIDS Clinical Trials Group (ACTG) study (protocol A5142). The study will determine which of these is the best regimen as part of a strategy for initial HIV therapy.
There are positives and negatives to each. Lipids increase with lopinavir/ritonavir but resistance to this drug is difficult develop. Efavirenz is generally well tolerated but does have important side effects and resistance to this agent is relatively easy to cultivate.
At the end of the day, which is better and will an NRTI-sparing regimen of these two titans alone be even better is a question that we shall have answered during the next year.
Right now, I use both options 2 and 3. I may tend to rely on Kaletra more for those with viral loads that are higher and CD4 counts that are lower. Often it is the ability of the patient to take pills, their pre-treatment lipids/diabetes status or their need/desire for a once a day regimen (efavirenz plus 2 NRTIs can be once daily) that sways me one way or the other.
I encourage anyone about to start HIV therapy, who lives in the US near an ACTG unit to consider joining this important study. The regimens, as stated above, are all potent and you may help determine what is the best all around initial HIV therapy.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.